1562 related articles for article (PubMed ID: 28916432)
1. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
[TBL] [Abstract][Full Text] [Related]
3. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M
Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Mohammad AJ; Hot A; Arndt F; Moosig F; Guerry MJ; Amudala N; Smith R; Sivasothy P; Guillevin L; Merkel PA; Jayne DR
Ann Rheum Dis; 2016 Feb; 75(2):396-401. PubMed ID: 25467294
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence.
Fanouriakis A; Kougkas N; Vassilopoulos D; Fragouli E; Repa A; Sidiropoulos P
Semin Arthritis Rheum; 2015 Aug; 45(1):60-6. PubMed ID: 25908179
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
8. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.
Mutoh T; Shirai T; Sato H; Fujii H; Ishii T; Harigae H
Rheumatol Int; 2022 Nov; 42(11):2069-2076. PubMed ID: 34287685
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
Teixeira V; Mohammad AJ; Jones RB; Smith R; Jayne D
RMD Open; 2019; 5(1):e000905. PubMed ID: 31245051
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
11. Severe cardiomyopathy revealing antineutrophil cytoplasmic antibodies-negative eosinophilic granulomatosis with polyangiitis.
Bouiller K; Samson M; Eicher JC; Audia S; Berthier S; Leguy V; Humbert O; Martin L; Lorgis L; Cottin Y; Bonnotte B; Lorcerie B
Intern Med J; 2014 Sep; 44(9):928-31. PubMed ID: 25201426
[TBL] [Abstract][Full Text] [Related]
12. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Pagnoux C; Groh M
Expert Rev Clin Immunol; 2016 Oct; 12(10):1059-67. PubMed ID: 27191665
[TBL] [Abstract][Full Text] [Related]
13. Churg-Strauss syndrome.
Greco A; Rizzo MI; De Virgilio A; Gallo A; Fusconi M; Ruoppolo G; Altissimi G; De Vincentiis M
Autoimmun Rev; 2015 Apr; 14(4):341-8. PubMed ID: 25500434
[TBL] [Abstract][Full Text] [Related]
14. B-cell-targeted therapy in systemic vasculitis.
Lally L; Spiera R
Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
Muñoz SA; Gandino IJ; Orden AO; Allievi A
Reumatol Clin; 2015; 11(3):165-9. PubMed ID: 25523986
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
Doubelt I; Pulenzas N; Carette S; Pagnoux C;
Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
[TBL] [Abstract][Full Text] [Related]
17. Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab.
Tsioulos G; Kounatidis D; Vallianou NG; Koufopoulos N; Katsimbri P; Antoniadou A
Am J Med Sci; 2023 Jan; 365(1):93-98. PubMed ID: 35970248
[TBL] [Abstract][Full Text] [Related]
18. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
19. An overlap of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Surendran S; Gundappa C; Gandhi A; Kurien AA; Fernando E
Saudi J Kidney Dis Transpl; 2017; 28(3):639-644. PubMed ID: 28540906
[TBL] [Abstract][Full Text] [Related]
20. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
